Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 7/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1632009 | 0.88 | RXRA (0.50) | RXRANR4A2AKR1B1OPRK1OPRM1 | |
| SCHEMBL401112 | 0.82 | RXRA (0.48) | RXRANR4A2OPRK1OPRM1OPRD1 | |
| SCHEMBL1629396 | 0.81 | OPRK1 (0.37) | AKR1B1OPRK1OPRM1OPRD1ESR1 | |
| SCHEMBL398475 | 0.81 | RXRA (0.47) | RXRANR4A2 | |
| SCHEMBL399111 | 0.81 | RXRA (0.47) | RXRANR4A2OPRK1OPRM1OPRD1 | |
| SCHEMBL13885429 | 0.81 | RXRA (0.47) | RXRANR4A2OPRK1OPRM1OPRD1 | |
| SCHEMBL15061011 | 0.80 | RXRA (0.46) | RXRANR4A2AKR1B1 | |
| SCHEMBL397406 | 0.77 | RXRA (0.41) | RXRANR4A2OPRK1OPRM1OPRD1 | |
| SCHEMBL401350 | 0.77 | RXRA (0.41) | RXRANR4A2OPRK1OPRM1OPRD1 | |
| SCHEMBL398267 | 0.75 | RXRA (0.41) | RXRANR4A2OPRK1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210008002-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-01-14 | — | — | US | disclosed |
| US-20170304216-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-10-26 | — | — | US | disclosed |
| US-20170304216-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-10-26 | — | — | US | disclosed |
| EP-2200994-B1 | CONDENSED COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARM INC (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2200994-B1 | CONDENSED COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARM INC (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8470872-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470872-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470872-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120088825-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088825-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8101651-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101651-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090131510-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. | 2009-05-21 | — | — | US | disclosed |
| US-20090131510-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008002-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | ESR2, ESRRG, ESR1 | RXRA 181/4885NR4A2 14/4885AKR1B1 817/4885 |
| US-20120088825-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ESRRB, ESR2, ESRRA | RXRA 35/4885NR4A2 94/4885AKR1B1 432/4885 |
| US-20170304216-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | ESR2, ESRRG, ESR1 | RXRA 181/4885NR4A2 14/4885AKR1B1 817/4885 |
| US-20090131510-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ESRRB, ESR2, ESRRA | RXRA 35/4885NR4A2 94/4885AKR1B1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.